Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Nov 11 2009

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data relating to Soliris^® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans. Physicians are also scheduled to report on their experience with eculizumab in patients with atypical Hemolytic Uremic Syndrome (aHUS) during the meeting. Abstracts summarizing these presentations were published today on the ASH web site and can be accessed using the links provided below. Soliris is a complement inhibitor approved for the treatment of PNH to reduce hemolysis. Soliris is currently under investigation for the treatment of aHUS.

The following abstract will be presented in a poster session on Saturday, December 5, 2009 from 5:30 – 7:30 p.m., Central Standard Time (CST):

“Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study,” Kanakura, et al.

Abstract: http://ash.confex.com/ash/2009/webprogram/Paper16844.html.

The following abstracts will be presented in a poster session on Sunday, December 6, 2009 from 6:00 – 8:00 p.m. CST:

“Successful Treatment of aHUS Recurrence and Arrest of Plasma Exchange Resistant TMA Post-Renal Transplantation with the Terminal Complement Inhibitor Eculizumab,” Legault and Boelkins.

Abstract: http://ash.confex.com/ash/2009/webprogram/Paper16845.html.

“Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency,” Schrezenmeier, et al. Poster II-979.

Abstract: http://ash.confex.com/ash/2009/webprogram/Paper16843.html.

“Identification and Clinical Significance of Type II Granulocytes Among Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Identified Using Multiparameter High-Sensitivity Flow Cytometry,” Movalia, et al.

Abstract: http://ash.confex.com/ash/2009/webprogram/Paper24600.html.

The following abstracts will be presented in a poster session on Monday, December 7, 2009 from 6:00 – 8:00 p.m. CST:

“Clinical Impact of Unregulated Terminal Complement Activity in Never-Transfused Patients with Paroxysmal Nocturnal Hemoglobinuria,” Muus, et al.

Abstract: http://ash.confex.com/ash/2009/webprogram/Paper18021.html.

“Terminal Complement Inhibitor Eculizumab Improves Complement-Mediated Platelet Consumption and Thrombocytopenia in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),” Socie, et al.

Abstract: http://ash.confex.com/ash/2009/webprogram/Paper18023.html.

SOURCE Alexion Pharmaceuticals, Inc.